DNA Methylation Clock Reversal — Gene Therapy & Genetic Interventions
Therapeutic interventions targeting the epigenetic clock to reverse biological age as measured by DNA methylation patterns.
Overview
DNA methylation clocks (Horvath, Hannum, GrimAge, PhenoAge, DunedinPACE) measure biological age by assessing CpG methylation patterns at specific genomic loci. These clocks predict mortality and morbidity better than chronological age. The TRIIM trial (Fahy et al., 2019) demonstrated a 2.5-year reversal in epigenetic age using a combination of growth hormone, DHEA, and metformin. Subsequent interventions including lifestyle changes, rapamycin, and partial reprogramming have shown methylation clock reversal. TET enzymes and DNMT inhibitors can directly modify methylation patterns, though targeted approaches are needed.
Indications
- Biological age acceleration
- Accelerated epigenetic aging syndromes
- Age-related disease prevention
- Longevity and healthspan optimization
- Biomarker-guided anti-aging interventions
Mechanism of Action
Genome-wide DNA methylation profiling at age-predictive CpG sites using Illumina arrays or nanopore sequencing
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| TRIIM Protocol (GH + DHEA + Metformin) | GH 0.015 mg/kg, DHEA 50 mg, Metformin 500 mg | Daily | As per Fahy et al. 2019; 12-month protocol |
| Targeted epigenetic editors (TET/DNMT) | Study-specific | Study-specific | Preclinical; CRISPRoff/CRISPRon platforms |
Evidence Grade
GRADE C
Safety & Contraindications
- Global demethylation agents (e.g., azacitidine) have significant toxicity and are not appropriate for anti-aging use
- Targeted epigenetic editing requires precise delivery to avoid unintended gene activation/silencing
- Methylation clock reversal does not guarantee functional rejuvenation
- Clock accuracy varies by tissue type and individual genetics
- Interventional approaches (TRIIM protocol) carry their own drug-specific risks